This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
Article Cite This: ACS Omega 2018, 3, 6867−6873
Nonprotecting Group Synthesis of a Phospholipase C Activatable Probe with an Azo-Free Quencher Benjamin K. Liebov,† Alejandro D. Arroyo, Natalia I. Rubtsova, Sofya A. Osharovich, E. James Delikatny, and Anatoliy V. Popov* Department of Radiology, University of Pennsylvania, 3620 Hamilton Walk, Philadelphia, Pennsylvania 19104, United States
Downloaded via 80.82.77.83 on June 30, 2018 at 02:32:20 (UTC). See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles.
S Supporting Information *
ABSTRACT: The near-infrared fluorescent activatable smart probe Pyro-phosphatidylethanolamine (PtdEtn)-QSY was synthesized and observed to selectively fluoresce in the presence of phosphatidylcholine-specific phospholipase C (PC-PLC). PC-PLC is an important biological target as it is known to be upregulated in a variety of cancers, including triple negative breast cancer. Pyro-PtdEtn-QSY features a QSY21 quenching moiety instead of the Black Hole Quencher-3 (BHQ-3) used previously because the latter contains an azo bond, which could lead to biological instability.
■
INTRODUCTION Advances in the field of molecular imaging represent an ongoing effort to improve the physician’s ability to detect, monitor, and treat a variety of diseases, including cancer.1 Linder et al. describes these advances in terms of the development of three classes of molecular imaging probes: nonspecific agents, which fluoresce permanently, a specific or targeted probe that contains a fluorophore, and an activatable smart probe with a fluorophore that will only fluoresce upon enzymatic cleavage or activation via another biological mechanism.2 In this paper, we report the synthesis of an activatable smart probe designed to detect enzyme activity in lipid metabolism with known cancerous associations. Lipids play an important role in biological systems as they are known to participate in the regulation of cell signaling.3 Because many cancers exhibit variations in their metabolic and signaling profiles, enzymes in lipid metabolism have become exciting targets for molecular imaging probes. Phosphocholine (PC) is a lipid metabolite that has been observed in increased levels in prostate,4−8 brain,4,6,9−12 and breast4,9,13−17 cancer cells and solid tumors. Elevated levels of PC have also been associated with the degree of malignancy,18−20 and decreased levels of PC are observed in response to chemotherapeutic treatment.21 PC has become an important and distinctive cancer biomarker. To detect PC by an activatable smart probe it is necessary to understand the surrounding biological processes. PC can be produced by multiple metabolic pathways, including the anabolic phosphorylation of choline by choline kinase or as the product of the catabolism of phosphatidylcholine by phospholipase C (PLC), along with diacylglycerol.22−28 These metabolic processes are considered a potential factor in the irregular choline metabolism observed in a variety of cancers.29−31 Elevated activity of phosphati© 2018 American Chemical Society
dylcholine-specific PLC (PC-PLC) has been observed in a variety of cancer types, including the triple negative breast cancer line, MDA-MB-231. 32 On the basis of these observations, our research efforts have centered on the development of molecular imaging probes that will selectively fluoresce in the presence of PC-PLC. Previously, we reported the synthesis and selectivity of an activatable smart probe that selectively fluoresces in the presence of PC-PLC.22−24 This specific activation is achieved by the precise construction of the probe based on a core structure of the phospholipid, phosphatidylethanolamine (PtdEtn). If left unmodified, PtdEtn can be enzymatically cleaved by a variety of enzymes. However, if a bulky moiety is placed at the sn-2 position of the glycerol backbone without a spacer, only cleavage by PC-PLC is observed.22 Our lab exploited this selective cleavage to design a next-generation activatable probe selective for PC-PLC. The final goal would be to design a probe that can more easily delineate cancerous tissue from healthy tissue. Along with the selectivity achieved by the PtdEtn backbone, to build the activatable probe, a precise fluorophore/quencher pair must be implemented. The former has already been explored in our previous research with the fluorophore, pyropheophorbide a (Pyro, λex = 410 and 665 nm; λem = 670−725 nm). Pyro achieves two goals: first, it is bulky enough to prevent cleavage of the phospholipid by any enzyme other than PC-PLC (as described above) and second, it fluoresces in the near-infrared (NIR) window. NIR fluorophores have been of interest recently because the NIR window is known for low Received: April 3, 2018 Accepted: June 18, 2018 Published: June 25, 2018 6867
DOI: 10.1021/acsomega.8b00635 ACS Omega 2018, 3, 6867−6873
Article
ACS Omega Scheme 1. Synthesis of Pyro-PtdEtn-BHQ
Scheme 2. Synthesis of Lyso-phosphatidylethanolamine (LysoPtdEtn)-QSY and Pyro-PtdEtn-QSY
In previously published papers, we reported the biological testing of Pyro-PtdEtn-BHQ against a series of phospholipases, including PC-PLC. Testing on cancer cells was carried out with DU145 human prostate cancer cell line, which has increased PC-PLC levels, and in vivo studies were performed on mouse models bearing DU145 tumors.22−24 Despite the success of Pyro-PtdEtn-BHQ, BHQ-3 has been shown to experience stability problems in vivo due to the presence of an azo bond in the structure.2,40−44 Moreover, the shelf-life of Pyro-PtdEtn-BHQ chloroform solution is less than 2 months, which makes it inconvenient for practical use as it requires freshly synthesized probes. The synthesis is complicated, and the overall yield of Pyro-PtdEtn-BHQ is as low as 15%.22 Because of the quenching range afforded by BHQ-3, it has been used in a variety of fluorescent probes.2,44 Unfortunately, as was just mentioned, one of the drawbacks noted for BHQ-3 is the instability in the azo bond present in its structure.2,40−44 A 2015 article published by Uddin et al. exploits the ease of cleavage of the azo bond of BHQ-3 as a probe activation mechanism to monitor hypoxia in mouse models.44 Although this example uses the azo bond for advantageous purposes, the
autofluorescence, minimal absorption by water and hemoglobin, and low tissue scattering. Notable examples are indocyanine green or IRDye 800CW, both of which fluoresce in the NIR window and can be observed by detectors with tissue depth penetration of up to 1 cm.2,33−36 The relative ease of detection of a NIR fluorophore like Pyro makes it an ideal candidate. An additional feature of Pyro is that it is a known photosensitizing agent, therefore our probe could be used not only for detection of cancer but also for treatment through the production of singlet oxygen when stimulated at the proper wavelength.37−39 Despite the utility of Pyro as a NIR fluorophore, to create an activatable smart probe, the fluorescence must be quenched when not in the presence of the activating enzyme, PC-PLC. This is achieved by coupling a quenching moiety to the smart probe. Previously, our laboratory used the NIR Black Hole Quencher-3 (BHQ-3, absorbance range 620−730 nm) because it precisely absorbed the fluorescence emitted by Pyro through Förster resonance energy transfer.22 The completed probe Pyro-PtdEtn-BHQ was successfully isolated by our lab (Scheme 1) and tested against various sources of PC-PLC. 6868
DOI: 10.1021/acsomega.8b00635 ACS Omega 2018, 3, 6867−6873
Article
ACS Omega
Figure 1. Selective cleavage of Pyro-PtdEtn-QSY by PC-PLC in a buffered solution compared to several different phospholipases: PC-PLC, SMase, sPLA2 (IB porcine), PLD, and buffer 140 mM NaCl−10 mM HEPES, pH 7.4 (control). No positive control was used.
decreased the yield of Pyro-PtdEtn (20%, Scheme 1).22 That is why this alteration most likely is responsible for the higher yield and cleaner product obtained. Once LysoPtdEtn-QSY was isolated, Pyro is coupled to the sn-2 position of the phospholipid using a carbodiimide, N-(3dimethylaminopropyl)-N′-ethyl carbodiimide hydrochloride (EDC·HCl). An excess of Pyro and EDC·HCl is used to drive the reaction toward the desired product, Pyro-PtdEtnQSY (Scheme 2). Initially, Pyro appears green but once incorporated into the probe, its fluorescence is quenched by QSY21 and the fully assembled probe, Pyro-PtdEtn-QSY, appears aquamarine. This stark color change between Pyro and Pyro-PtdEtn-QSY simplifies the product isolation using column chromatography. The overall yield of Pyro-PtdEtnQSY was as high as 61%, more than 4 times higher than for Pyro-PtdEtn-BHQ.22 The shelf-life of Pyro-PtdEtn-QSY chloroform solution by now is more than 8 months, which makes it an ideal probe for practical use. With Pyro-PtdEtn-QSY in hand, we set out to test its selective activation by PC-PLC. To confirm its specificity, the probe was exposed to PC-PLC as well as several other phospholipases, including sphingomyelinase (SMase), sPLA2 (IB porcine), and phospholipase D (PLD). In this (and next) experiment, the probe was incorporated into lipid nanoparticles (LNP) in 140 mM NaCl−10 mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) buffer, pH 7.4, which we have previously found optimal for LNP stability and in vitro experiments.59 It was excited at 409 nm, and emission was measured at 665 nm on a plate reader (SpectraMax M5, Molecular Devices). When Pyro-PtdEtnQSY was exposed to PC-PLC, an increase of fluorescence was observed, whereas the other phospholipases did not yield any significant increase in fluorescence (Figure 1). Because of the success of the initial enzyme tests, further experiments were conducted to see if the fluorescence of PyroPtdEtn-QSY could be restored when exposed to PC-PLC under conditions more closely related to the intended translational use of the probe. Rather than excitation and emission experiments conducted at a single wavelength in a plate reader, we used an IVIS Spectrum imaging system with an excitation filter range of 415−445 nm (430 nm filter) and detected the emission in the 650−670 nm range (660 nm filter). For this, Pyro-PtdEtn-QSY was exposed to a buffered solution (140 mM NaCl−10 mM HEPES, pH 7.4, control) and several phospholipase isoforms, as described above. The
bulk of the literature on BHQ-3 describes a molecule with excellent quenching potential but with the potential for structural instability.2,40−44 An alternative quenching moiety with similar quenching capabilities but without an unstable azo bond could lead to a new generation of more stable activatable probes. In this paper, we present the development of a new activatable smart probe that incorporates an alternative, more stable quenching moiety: QSY21, which has a similar quenching range (580−720 nm) to BHQ-3 (620−730 nm). Both quench in the NIR range, but their difference lies in their structures as QSY21 does not contain an azo bond (see structure in Scheme 2) and is therefore considered to be more stable. Moreover, a variety of activatable smart probes have already been synthesized using QSY21 to detect biological processes.42,45−58 This paper presents the synthesis and initial biological evaluation of the novel PC-PLC selective probe, Pyro-PtdEtn-QSY.
■
RESULTS AND DISCUSSION When the initial Pyro-PtdEtn-BHQ activatable probe was developed, it required the use of a BOC-protected phosphatidylethanolamine (LysoPtdEtn-BOC, see Scheme 1). By protecting the primary amine of the phospholipid we were able to prevent the coupling of the Pyro moiety at that position and saw exclusive substitution at the desired sn-2 position, which is required to achieve selective cleavage via PCPLC.22 Although the use of the LysoPtdEtn-BOC was feasible, it would have been more economical to use the unprotected phospholipid LysoPtdEtn. Unfortunately, when BHQ-3-SE was reacted with unprotected LysoPtdEtn, the desired product, LysoPtdEtn-BHQ, could not be isolated. However, when unprotected conditions were tested using the azo-free quenching moiety, QSY21 (as succinimidyl ester, QSY21-SE), the desired product, LysoPtdEtn-QSY, was isolated in decent yield as a blue oil (Scheme 2). A detected side product was the product of hydrolysis of QSY21-SE; this did not inhibit the production or isolation of LysoPtdEtn-QSY. Not using a BOC protecting group proved to be not only financially advantageous but it also reduced the number of synthetic steps as we no longer had to remove the protecting group. An additional disadvantage of BOC-deprotecting step was partial chemical cleavage of ester bonds at the glycerol backbone under the strong acidic conditions that dramatically 6869
DOI: 10.1021/acsomega.8b00635 ACS Omega 2018, 3, 6867−6873
Article
ACS Omega
purchased from Fisher Scientific. Pyropheophorbide a (Pyro) was purchased from Frontier Scientific, Newark, DE. 1Palmitoyl-2-hydroxy-sn-glycero-phosphoethanolamine (16:0 Lyso-phosphatidylethanolamine, LysoPtdEtn) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] ammonium salt (DSPEPEG2000) in chloroform, 5 mg/mL, were purchased from Avanti Polar Lipids, Inc., Alabaster, AL. QSY21 succinimidyl ester (QSY-SE) was purchased from Thermo Fisher Scientific, Grand Island, NY. Other reagents/reactants were purchased from Sigma-Aldrich and used without further purification. Silica diol (Premium RF, 70A, 40−75 μm, product # - 6257001) and silica diol thin-layer chromatography plates (w/ UV254, glass backed, 200 μm, 10 × 20 cm 25/pk, product # 2914136) were purchased from Sorbtech Chromatography, Norcross, GA. All chemical reactions with QSY21 and/or Pyro were carried out in the dark under dry Ar. Matrix assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectra were recorded on a Bruker Ultraflex III MALDI TOF/TOF (Bruker Daltonics, Billerica, MA) using positivemode ionization with a terthiophene (Ter; 2,2′:5′,2″terthiophene) matrix. Absorbance and fluorescence data, as well as time-dependent release of fluorescence, were measured using a SpectraMax M5 fluorescent plate reader (Molecular Devices, San Jose, CA) and an IVIS Spectrum in vivo imaging system (PerkinElmer, Hopkinton, MA). Phospholipases. Phospholipases were obtained from Sigma-Aldrich (St. Louis, MO), dissolved in 140 mM NaCl− 10 mM HEPES buffer, pH = 7.4, and stored in aliquots at −80 °C. Mammalian phospholipase isoforms were used whenever available: sPLA2 (type IB, porcine pancreas), otherwise bacterial isoforms were employed: PC-PLC (Bacillus cereus), SMase (Benthesicymus cereus), and PC-PLD (Streptomyces chromofuscus). Experimental Procedures. Synthesis of LysoPtdEtn-QSY. LysoPtdEtn (0.050 g, 0.110 mmol) and QSY-SE (0.020 g, 0.0245 mmol) were added to a 100 mL round-bottom flask with stir bar, followed by dry acetonitrile (∼50 mL), diisopropylethylamine (40 μL, 0.230 mmol), and 4(dimethylamino)pyridine (DMAP, 0.0087 g, 0.0712 mmol). The reaction flask was purged with argon and covered in aluminum foil. The blue reaction solution was stirred for 2 days. Reaction progress was tested via thin-layer chromatography (TLC) on functionalized silica diol (Sorbtech cat # 2933187) using a methanol/chloroform solution (5:95). The product was observed at Rf = 0.47. The reaction solution was concentrated in vacuo until ∼3 mL remained. The reaction solution was loaded onto a silica diol (Sorbtech cat # 6257001) column. A gradient of methanol/chloroform eluent was used (0:100 to 20:80) to elute several blue fractions. The blue fractions were tested via TLC, and on the basis of these results, the proper fractions were concentrated to a dark blue oil. The oil was left under vacuum overnight to reveal the product (0.0239 g, 0.0214 mmol, 87% yield). The product, LysoPtdEtn-QSY, was confirmed by MALDI mass spectrometry and UV−vis spectrometry (Supporting Information, SI). Synthesis of Pyro-PtdEtn-QSY. LysoPtdEtn-QSY (0.0190 g, 0.0170 mmol) was put into a 20 dram vial charged with a stir bar, followed by Pyro (0.0118 g, 0.0542 mmol), N-(3dimethylaminopropyl)-N′-ethyl carbodiimide hydrochloride (EDC·HCl, 0.1848 g, 0.9640 mmol), DMAP (0.0225 g, 0.1841 mmol), and dry dichloromethane (∼4 mL). The reaction vial was purged with argon, covered in foil, and
results of this experiment are evident from Figure 2. Fluorescence is observed almost immediately only when
Figure 2. Broad-range fluorescence experiments of selective cleavage of Pyro-PtdEtn-QSY by a buffered solution 140 mM NaCl−10 mM HEPES, pH 7.4 (control), and several different phospholipase isoforms (sPLA2 (IB porcine), PLD, and PC-PLC). No positive control was used.
Pyro-PtdEtn-QSY is exposed to PC-PLC. The fluorescence continues to increase with time, whereas the buffered control, PLD, and sPLA2 (IB porcine) experiments remain quenched even after 6 h. This experiment confirms the conclusions of previous enzyme tests, demonstrating that Pyro-PtdEtn-QSY is successfully quenched until it is exposed to PC-PLC and fluorescence is restored. Moreover, this study is more accurate in confirming the potential translational use of the probe as a detector for PC-PLC in in vitro and in vivo models.
■
CONCLUSIONS The NIR fluorescent probe Pyro-PtdEtn-QSY shows remarkable selectivity for PC-PLC. The synthesis of the probe does not require the use of protecting group chemistry essentially skipping a step that had been previously required for a PCPLC selective probe. Additionally, probe stability is increased using a quenching moiety that does not have an azo bond. This structural change could lead to increased stability when exposed to biological conditions. Therefore, Pyro-PtdEtnQSY is an excellent candidate for in vitro and in vivo studies of cancer cell types with increased PC-PLC levels, such as MDAMB-231, triple negative breast cancer.25
■
EXPERIMENTAL PART Materials and General Methods. Dry solvents were purchased from Acros Organics. Regular solvents were 6870
DOI: 10.1021/acsomega.8b00635 ACS Omega 2018, 3, 6867−6873
Article
ACS Omega allowed to stir for 72 h. The reaction was monitored by TLC on silica diol plates (5:95, methanol/chloroform) until an aquamarine spot appeared at Rf = 0.6. The reaction solution was loaded onto a silica diol (Sorbtech cat # 62570-01) column (∼0.5 cm). Methanol/chloroform (1:99) was used to elute an aquamarine band. The aquamarine band was concentrated to an oil and placed under vacuum overnight to yield an aquamarine oil. The oil was then picked up in minimal chloroform and placed on a silica diol preparative TLC plate. The plate was eluted with 10:90 methanol/ chloroform. An aquamarine band was collected between Rf’s 0.70 and 0.75. The silica was collected and stirred with 10:90 methanol/chloroform. After filtering off the sorbent, the solution was concentrated and underwent second preparative TLC to get rid of fluorescent impurities (Pyro acid). The product was isolated as an oil that was lyophilized overnight (0.0194 g, 0.0119 mmol, 70% yield). The overall yield after two-step synthesis is 61%. The product was confirmed by MALDI mass spectrometry and UV−vis spectrometry (SI). Preparation of Pyro-PtdEtn-QSY-Loaded Lipid Nanoparticles. DSPE-PEG2000 (1 mL of 5 mg/mL solution in CHCl3, 1.78 μmol, 97% mol) and Pyro-PtdEtn-QSY in CHCl3 (55 nmol, 3% mol) were mixed in a 15 mL glass flask. (PyroPtdEtn-QSY concentration in the initial chloroform solution was determined using the Beer−Lambert law by measuring the optical density at 410 nm and employing an extinction coefficient of 110 000 M/cm.) The solvent was evaporated under nitrogen flow. The obtained lipid film was dried under high vacuum overnight. The flask was then flushed with Ar and held in the water bath at 80 °C for 3 min, then rehydrated with 1 mL of hot (80 °C) degassed buffer solution under Ar flow. Buffer (140 mM NaCl−10 mM HEPES) was used at pH 7.4. The mixture was vortexed until an optically clear dispersion was obtained and allowed to cool down. Upon reaching room temperature, the solution was filtered through a 0.22 μm MILLEX-GV filter. Enzyme-Mediated Probe Cleavage. Fluorescence experiments: 90 μL of phospholipase solution in buffer (140 mM NaCl−10 mM HEPES, pH = 7.4) was placed into a black wall flat clear bottom 96-well plate (10 units per well). PyroPtdEtn-QSY lipid dispersion (10 μL) in buffer (140 mM NaCl−10 mM HEPES, pH = 7.4) was added to the phospholipase to a final concentration of 1 mM. Fluorescence was monitored over time at 37 °C on a Molecular Devices SpectraMax M5 plate reader under excitation 409 nm and emission 665 nm. Enzyme-Mediated Probe Cleavage: IVIS Spectrum Experiments. The IVIS Spectrum (PerkinElmer, Hopkinton, MA) is an advanced preclinical optical imaging system ideal for fluorescence imaging in vivo and in vitro. Black wall clear bottom 96-well plates were prepared as above with solutions of 1 mM Pyro-PtdEtn-QSY and 10 units of phospholipases in 140 mM NaCl−10 mM HEPES buffer, pH = 7.4. Fluorescence was monitored over time at 37 °C with excitation between 415 and 445 nm (430 nm filter) and emission at 650−670 nm (660 nm filter).
■
■
Spectroscopic data for the characterization of PtdEtnQSY and Pyro-PtdEtn-QSY (PDF)
AUTHOR INFORMATION
Corresponding Author
*E-mail:
[email protected]. ORCID
Anatoliy V. Popov: 0000-0002-4678-6307 Present Address †
Adesis, Inc., 27 McCullough Drive, New Castle, Delaware 19720, United States (B.K.L.). Notes
The authors declare no competing financial interest.
■
ACKNOWLEDGMENTS This work was supported by the National Cancer Institute (NCI) grant, R01-CA201328-01. B.K.L.’s, N.I.R.’s, and A.V.P.’s work was partially supported by R01-NS100892-1. Imaging was performed at the University of Pennsylvania Small Animal Imaging Facility (SAIF).
■
REFERENCES
(1) Weissleder, R. Molecular Imaging in Cancer. Science 2006, 312, 1168−1171. (2) Linder, K. E.; Metcalfe, E.; Nanjappan, P.; Arunachalam, T.; Ramos, K.; Skedzielewski, T. M.; Marinelli, E. R.; Tweedle, M. F.; Nunn, A. D.; Swenson, R. E. Synthesis, In Vitro Evaluation, and In Vivo Metabolism of Fluor/Quencher Compounds Containing IRDye 800CW and Black Hole Quencher-3 (BHQ-3). Bioconjugate Chem. 2011, 22, 1287−1297. (3) Eyster, K. M. The membrane and lipids as integral participants in signal transduction: lipid signal transduction for the non-lipid biochemist. Adv. Physiol. Educ. 2007, 31, 5−16. (4) Negendank, W. Studies of human tumors by MRS: a review. NMR Biomed. 1992, 5, 303−324. (5) Ackerstaff, E.; Pflug, B. R.; Nelson, J. B.; Bhujwalla, Z. M. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001, 61, 3599−3603. (6) Kurhanewicz, J.; Vigneron, D. B.; Nelson, S. J. Threedimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia 2000, 2, 166−189. (7) Swindle, P.; McCredie, S.; Russell, P.; Himmelreich, U.; Khadra, M.; Lean, C.; Mountford, C. Pathologic characterization of human prostate tissue with proton MR spectroscopy. Radiology 2003, 228, 144−151. (8) Milkevitch, M.; Shim, H.; Pilatus, U.; Pickup, S.; Wehrle, J. P.; Samid, D.; Poptani, H.; Glickson, J. D.; Delikatny, E. J. Increases in NMR-visible lipid and glycerophosphocholine during phenylbutyrateinduced apoptosis in human prostate cancer cells. Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2005, 1734, 1−12. (9) Podo, F. Tumour phospholipid metabolism. NMR Biomed. 1999, 12, 413−439. (10) Bhakoo, K. K.; Williams, S. R.; Florian, C. L.; Land, H.; Noble, M. D. Immortalization and transformation are associated with specific alterations in choline metabolism. Cancer Res. 1996, 56, 4630−4635. (11) Li, X.; Lu, Y.; Pirzkall, A.; McKnight, T.; Nelson, S. J. Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients. J. Magn. Reson. Imaging 2002, 16, 229− 237. (12) Maris, J. M.; Evans, A. E.; McLaughlin, A. C.; D’Angio, G. J.; Bolinger, L.; Manos, H.; Chance, B. 31P nuclear magnetic resonance spectroscopic investigation of human neuroblastoma in situ. N. Engl. J. Med. 1985, 312, 1500−1505.
ASSOCIATED CONTENT
S Supporting Information *
The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsomega.8b00635. 6871
DOI: 10.1021/acsomega.8b00635 ACS Omega 2018, 3, 6867−6873
Article
ACS Omega (13) Jacobs, M. A.; Barker, P. B.; Bottomley, P. A.; Bhujwalla, Z.; Bluemke, D. A. Proton magnetic resonance spectroscopic imaging of human breast cancer: a preliminary study. J. Magn. Reson. Imaging 2004, 19, 68−75. (14) Singer, S.; Souza, K.; Thilly, W. G. Pyruvate utilization, phosphocholine and adenosine triphosphate (ATP) are markers of human breast tumor progression: a 31P- and 13C-nuclear magnetic resonance (NMR) spectroscopy study. Cancer Res. 1995, 55, 5140− 5145. (15) Katz-Brull, R.; Degani, H. Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res. 1996, 16, 1375−1379. (16) Gribbestad, I. S.; Sitter, B.; Lundgren, S.; Krane, J.; Axelson, D. Metabolite composition in breast tumors examined by proton nuclear magnetic resonance spectroscopy. Anticancer Res. 1999, 19, 1737− 1746. (17) Glunde, K.; Jie, C.; Bhujwalla, Z. M. Molecular Causes of the Aberrant Choline Phospholipid Metabolism in Breast Cancer. Cancer Res. 2004, 64, 4270−4276. (18) Eliyahu, G.; Kreizman, T.; Degani, H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int. J. Cancer 2007, 120, 1721−1730. (19) Katz-Brull, R.; Seger, D.; Rivenson-Segal, D.; Rushkin, E.; Degani, H. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res. 2002, 62, 1966−1970. (20) Aboagye, E. O.; Bhujwalla, Z. M. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999, 59, 80−84. (21) Al-Saffar, N. M. S.; Troy, H.; Ramirez de Molina, A.; Jackson, L. E.; Madhu, B.; Griffiths, J. R.; Leach, M. O.; Workman, P.; Lacal, J. C.; Judson, I. R.; Chung, Y.-L. Noninvasive Magnetic Resonance Spectroscopic Pharmacodynamic Markers of the Choline Kinase Inhibitor MN58b in Human Carcinoma Models. Cancer Res. 2006, 66, 427−434. (22) Popov, A. V.; Mawn, T. M.; Kim, S.; Zheng, G.; Delikatny, E. J. Design and Synthesis of Phospholipase C and A2-Activatable NearInfrared Fluorescent Smart Probes. Bioconjugate Chem. 2010, 21, 1724−1727. (23) Mawn, T. M.; Popov, A. V.; Delikatny, E. J. A quantitative continuous enzyme assay of intramolecularly quenched fluorogenic phospholipase substrates for molecular imaging. Anal. Biochem. 2012, 422, 96−102. (24) Mawn, T. M.; Popov, A. V.; Beardsley, N. J.; Stefflova, K.; Milkevitch, M.; Zheng, G.; Delikatny, E. J. In Vivo Detection of Phospholipase C by Enzyme-Activated Near-Infrared Probes. Bioconjugate Chem. 2011, 22, 2434−2443. (25) Kumar, M.; Arlauckas, S. P.; Saksena, S.; Verma, G.; Ittyerah, R.; Pickup, S.; Popov, A. V.; Delikatny, E. J.; Poptani, H. Magnetic Resonance Spectroscopy for Detection of Choline Kinase Inhibition in the Treatment of Brain Tumors. Mol. Cancer Ther. 2015, 14, 899− 908. (26) Chiorazzo, M. G.; Bloch, N. B.; Popov, A. V.; Delikatny, E. J. Synthesis and Evaluation of Cytosolic Phospholipase A2 Activatable Fluorophores for Cancer Imaging. Bioconjugate Chem. 2015, 26, 2360−2370. (27) Arlauckas, S. P.; Popov, A. V.; Delikatny, E. J. Choline kinase alpha-Putting the ChoK-hold on tumor metabolism. Prog. Lipid Res. 2016, 63, 28−40. (28) Arlauckas, S. P.; Popov, A. V.; Delikatny, E. J. Direct Inhibition of Choline Kinase by a Near-Infrared Fluorescent Carbocyanine. Mol. Cancer Ther. 2014, 13, 2149−2158. (29) Podo, F.; Ferretti, A.; Knijn, A.; Zhang, P.; Ramoni, C.; Barletta, B.; Pini, C.; Baccarini, S.; Pulciani, S. Detection of phosphatidylcholine-specific phospholipase C in NIH-3T3 fibroblasts and their H-ras transformants: NMR and immunochemical studies. Anticancer Res. 1996, 16, 1399−1412. (30) Ferretti, A.; Podo, F.; Carpinelli, G.; Chen, L.; Borghi, P.; Masella, R. Detection of neutral active phosphatidylcholine-specific
phospholipase C in Friend leukemia cells before and after erythroid differentiation. Anticancer Res. 1993, 13, 2309−2317. (31) Xingzhong, W.; Lu, H.; Zhou, L.; Huang, Y.; Chen, H. Changes of phosphatidylcholine-specific phospholipase C in hepatocarcinogenesis and in the proliferation and differentiation of rat liver cancer cells. Cell Biol. Int. 1997, 21, 375−381. (32) Abalsamo, L.; Spadaro, F.; Bozzuto, G.; Paris, L.; Cecchetti, S.; Lugini, L.; Iorio, E.; Molinari, A.; Ramoni, C.; Podo, F. Inhibition of phosphatidylcholine-specific phospholipase C results in loss of mesenchymal traits in metastatic breast cancer cells. Breast Cancer Res. 2012, 14, R50. (33) Tromberg, B. J.; Zhang, Z.; Leproux, A.; O’Sullivan, T. D.; Cerussi, A. E.; Carpenter, P. M.; Mehta, R. S.; Roblyer, D.; Yang, W.; Paulsen, K. D.; Pogue, B. W.; Jiang, S.; Kaufman, P. A.; Yodh, A. G.; Chung, S. H.; Schnall, M.; Snyder, B. S.; Hylton, N.; Boas, D. A.; Carp, S. A.; Isakoff, S. J.; Mankoff, D. Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging. Cancer Res. 2016, 76, 5933− 5944. (34) Teraphongphom, N.; Rosenthal, E. L.; Kong, C. S.; Warram, J. M. Specimen mapping in head and neck cancer using fluorescence imaging. Laryngoscope Invest. Otolaryngol. 2017, 2, 447−452. (35) O’Sullivan, T. D.; Cerussi, A. E.; Cuccia, D. J.; Tromberg, B. J. Diffuse optical imaging using spatially and temporally modulated light. J Biomed. Opt. 2012, 17, No. 071311. (36) Durduran, T.; Choe, R.; Baker, W. B.; Yodh, A. G. Diffuse Optics for Tissue Monitoring and Tomography. Rep. Prog. Phys. 2010, 73, No. 076701. (37) Liu, H.; Zhao, M.; Wang, J.; Pang, M.; Wu, Z.; Zhao, L.; Yin, Z.; Hong, Z. Photodynamic therapy of tumors with pyropheophorbide-a-loaded polyethylene glycol-poly(lactic-co-glycolic acid) nanoparticles. Int. J. Nanomed. 2016, 11, 4905−4918. (38) Cheng, J.; Tan, G.; Li, W.; Li, J.; Wang, Z.; Jin, Y. Preparation, characterization and in vitro photodynamic therapy of a pyropheophorbide-a-conjugated Fe3O4 multifunctional magnetofluorescence photosensitizer. RSC Adv. 2016, 6, 37610−37620. (39) Zhou, A.; Wei, Y.; Wu, B.; Chen, Q.; Xing, D. Pyropheophorbide A and c(RGDyK) Comodified Chitosan-Wrapped Upconversion Nanoparticle for Targeted Near-Infrared Photodynamic Therapy. Mol. Pharmaceutics 2012, 9, 1580−1589. (40) TM, G. L. BBQ-650 (Black Berry Quencher 650). http://www. genelink.com/newsite/products/mod_detail.asp?modid=240. (41) Technologies, L. B. BHQ-3 Carboxylic Acid FAQs. https:// www.biosearchtech.com/products/synthesis-reagents/carboxylicacid-succinimidyl-esters/bhq3-carboxylic-acid#?tab=page_8916. (42) Guo, Z.; Park, S.; Yoon, J.; Shin, I. Recent progress in the development of near-infrared fluorescent probes for bioimaging applications. Chem. Soc. Rev. 2014, 43, 16−29. (43) Simard, B.; Tomanek, B.; van Veggel, F. C. J. M.; Abulrob, A. Optimal dye-quencher pairs for the design of an “activatable” nanoprobe for optical imaging. Photochem. Photobiol. Sci. 2013, 12, 1824−1829. (44) Uddin, M. I.; Evans, S. M.; Craft, J. R.; Marnett, L. J.; Uddin, M. J.; Jayagopal, A. Applications of Azo-Based Probes for Imaging Retinal Hypoxia. ACS Med. Chem. Lett. 2015, 6, 445−449. (45) Ballerstadt, R.; Gowda, A.; McNichols, R. Fluorescence Resonance Energy Transfer-Based Near-Infrared Fluorescence Sensor for Glucose Monitoring. Diabetes Technol. Ther. 2004, 6, 191−200. (46) de la Zerda, A.; Bodapati, S.; Teed, R.; May, S. Y.; Tabakman, S. M.; Liu, Z.; Khuri-Yakub, B. T.; Chen, X.; Dai, H.; Gambhir, S. S. Family of Enhanced Photoacoustic Imaging Agents for HighSensitivity and Multiplexing Studies in Living Mice. ACS Nano 2012, 6, 4694−4701. (47) Jolivel, V.; Arthaud, S.; Botia, B.; Portal, C.; Delest, B.; Clave, G.; Leprince, J.; Romieu, A.; Renard, P.-Y.; Touzani, O.; Ligeret, H.; Noack, P.; Massonneau, M.; Fournier, A.; Vaudry, H.; Vaudry, D. Biochemical Characterization of a Caspase-3 Far-red Fluorescent Probe for Non-invasive Optical Imaging of Neuronal Apoptosis. J. Mol. Neurosci. 2014, 54, 451−462. 6872
DOI: 10.1021/acsomega.8b00635 ACS Omega 2018, 3, 6867−6873
Article
ACS Omega (48) Kokko, T.; Kokko, L.; Loevgren, T.; Soukka, T. Homogeneous Noncompetitive Immunoassay for 17β-Estradiol Based on Fluorescence Resonance Energy Transfer. Anal. Chem. 2007, 79, 5935− 5940. (49) Le Reste, L.; Hohlbein, J.; Gryte, K.; Kapanidis, A. N. Characterization of Dark Quencher Chromophores as Nonfluorescent Acceptors for Single-Molecule FRET. Biophys. J. 2012, 102, 2658− 2668. (50) Li, X.; Mu, J.; Liu, F.; Tan, E. W. P.; Khezri, B.; Webster, R. D.; Yeow, E. K. L.; Xing, B. Human Transport Protein Carrier for Controlled Photoactivation of Antitumor Prodrug and Real-Time Intracellular Tumor Imaging. Bioconjugate Chem. 2015, 26, 955−961. (51) Madiyar, F. R.; Bhana, S.; Swisher, L. Z.; Culbertson, C. T.; Huang, X.; Li, J. Integration of a nanostructured dielectrophoretic device and a surface-enhanced Raman probe for highly sensitive rapid bacteria detection. Nanoscale 2015, 7, 3726−3736. (52) Ofori, L. O.; Withana, N. P.; Prestwood, T. R.; Verdoes, M.; Brady, J. J.; Winslow, M. M.; Sorger, J.; Bogyo, M. Design of Protease Activated Optical Contrast Agents That Exploit a Latent Lysosomotropic Effect for Use in Fluorescence-Guided Surgery. ACS Chem. Biol. 2015, 10, 1977−1988. (53) Ogawa, M.; Kosaka, N.; Choyke, P. L.; Kobayashi, H. TumorSpecific Detection of an Optically Targeted Antibody Combined with a Quencher-Conjugated Neutravidin “Quencher-Chaser”: A Dual “Quench and Chase” Strategy to Improve Target to Nontarget Ratios for Molecular Imaging of Cancer. Bioconjugate Chem. 2009, 20, 147− 154. (54) Sun, X.; Zhang, A.; Baker, B.; Sun, L.; Howard, A.; Buswell, J.; Maurel, D.; Masharina, A.; Johnsson, K.; Noren, C. J.; Xu, M.-Q.; Correa, I. R. Development of SNAP-Tag Fluorogenic Probes for Wash-Free Fluorescence Imaging. ChemBioChem 2011, 12, 2217− 2226. (55) Verdoes, M.; Oresic Bender, K.; Segal, E.; van der Linden, W. A.; Syed, S.; Withana, N. P.; Sanman, L. E.; Bogyo, M. Improved Quenched Fluorescent Probe for Imaging of Cysteine Cathepsin Activity. J. Am. Chem. Soc. 2013, 135, 14726−14730. (56) Xing, B.; Khanamiryan, A.; Rao, J. Cell-permeable near-infrared fluorogenic substrates for imaging β-lactamase activity. J. Am. Chem. Soc. 2005, 127, 4158−4159. (57) Zhang, S.; Metelev, V.; Tabatadze, D.; Zamecnik, P.; Bogdanov, A., Jr. Near-Infrared Fluorescent Oligodeoxyribonucleotide Reporters for Sensing NF-κB DNA Interactions In Vitro. Oligonucleotides 2008, 18, 235−243. (58) Zou, P.; Ting, A. Y. Imaging LDL Receptor Oligomerization during Endocytosis Using a Co-internalization Assay. ACS Chem. Biol. 2011, 6, 308−313. (59) Anikeeva, N.; Sykulev, Y.; Delikatny, E. J.; Popov, A. V. Corebased lipid nanoparticles as a nanoplatform for delivery of nearinfrared fluorescent imaging agents. Am. J. Nucl. Med. Mol. Imaging 2014, 4, 507−524.
6873
DOI: 10.1021/acsomega.8b00635 ACS Omega 2018, 3, 6867−6873
